Skip to main content
TipRanks
Go Ultimate75% OFF

Almeda Pu (AMDA) AI Stock Analysis

0 Followers
IL:AMDA

Almeda Pu

(TASE:AMDA)

Select Model
Rating:59Neutral
Price Target:ILA 174.00â–¼(-0.11% Downside)
Action:downgraded
Date:11/07/26

The overall score of 59 reflects a high-risk, high-reward profile. The primary strength is a rock-solid, debt-free balance sheet combined with superficially attractive valuation metrics. However, these positives are severely undermined by two critical risks: a complete disconnect between reported net income and negative operating cash flow, which questions the sustainability of the business model, and extremely overbought technical conditions that signal a high probability of a near-term price correction.

Positive Factors
Zero-debt balance sheetThe absence of debt gives the company substantial financial flexibility and avoids recurring interest obligations. This conservative capital structure can help preserve resilience through operating volatility, support investment when opportunities arise, and reduce refinancing pressure over the next several quarters.
Negative Factors
Persistent negative cash flowRecurring negative operating and free cash flow is a material fundamental weakness because reported earnings are not currently converting into liquidity. If the pattern persists, cash resources could face pressure, limiting internally funded growth and increasing reliance on balance-sheet resources to sustain operations.

Almeda Pu (AMDA) vs. iShares MSCI Israel ETF (EIS)

-25%0%25%50%75%100%125%150%IL:AMDA+39.76%EIS+10.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 33.79M
Dividend Yield
108.69%
Average Volume (3M)
37.30K
Price to Earnings (P/E)
1.0
Beta (1Y)
-0.13
Revenue Growth
-52.44%
EPS Growth
―
Country
Israel
Employees
2
Sector
General
Sector Strength
55
Industry
Asset Management

Almeda Pu Business Overview & Revenue Model

Company Description

Almeda Ventures Limited Partnership, established in Tel Aviv, Israel, in 2020, functions as a venture capital firm. The partnership strategically deploys capital across various development stages, including seed, startup, early-stage, and established...

Almeda Pu Financial Statement Overview

Summary

Financial performance is a tale of two stories. The income statement shows a remarkable turnaround with $10.7M in TTM revenue and a 92.8% net margin, and the balance sheet is pristine with zero debt and a 35.2% ROE. However, the cash flow statement is deeply concerning, with negative $982K in operating cash flow despite $10.0M in net income, indicating poor earnings quality. The overall score is weighed down significantly by the cash flow weakness.

Income Statement

75Positive

Balance Sheet

90Very Positive

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue10.74M87.68K-3.02M-292.00K907.00K1.60M
Gross Profit10.73M-57.37K-3.04M-328.00K852.00K1.56M
EBITDA9.94M1.91M-4.28M-1.55M-562.00K98.00K
Net Income9.97M1.89M-4.20M-1.58M-641.00K52.00K
Balance Sheet
Total Assets30.87M25.96M23.08M25.71M27.28M27.91M
Cash, Cash Equivalents and Short-Term Investments13.33M4.40M2.35M2.91M5.93M9.54M
Total Debt0015.00K73.00K147.00K243.00K
Total Liabilities93.00K125.03K442.00K405.00K393.00K545.00K
Stockholders Equity30.78M25.84M22.64M25.31M26.88M27.37M
Cash Flow
Free Cash Flow-982.00K-1.07M-1.09M-1.13M-1.46M-1.29M
Operating Cash Flow-982.00K-1.07M-1.09M-1.13M-1.46M-1.28M
Investing Cash Flow13.23M-476.29K-1.41M-3.57M-2.15M-9.93M
Financing Cash Flow-947.00K1.54M1.48M-73.00K59.00K8.24M

Almeda Pu Technical Analysis

Technical Analysis SentimentNegative
Last Price174.20

Price Trends

50DMA239.47Negative
100DMA229.98Negative
200DMA204.59Negative

Market Momentum

MACD-21.29Positive
RSI29.59Positive
STOCH21.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:AMDA, the sentiment is Negative. The current price of 174.20 is below the 20-day moving average (MA) of 221.65, below the 50-day MA of 239.47, and below the 200-day MA of 204.59, indicating a bearish trend. The MACD of -21.29 indicates Positive momentum. The RSI at 29.59 is Positive, neither overbought nor oversold. The STOCH value of 21.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:AMDA.

Almeda Pu Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IL:AMDA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IL:AMDAIL:AMDA59NeutralILS 34.37M1.03―108.69%-52.44%―
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IL:BLRXIL:BLRX41NeutralILS 29.87M-0.99――-93.07%62.25%
IL:CANFIL:CANF38UnderperformILS 16.21M-0.22――――

* General Sector Average

Performance Comparison

0%50000%100000%IL:AMDAIL:CBIIL:BLRXIL:CANFIL:ALMDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IL:AMDA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:AMDAAlmeda Ventures Limited Partnership174.2040.6430.43%
IL:CBIClal Biotechnology Industries Ltd19.80-14.20-41.76%
IL:BLRXBioLineRX Ltd.1.00-0.90-47.37%
IL:CANFCan-Fite BioPharma Ltd.268.70267.7026770.00%
IL:ALMDAllmed Solutions Ltd.29.40-2.10-6.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026